← Back
Data updated: Jun 28, 2026
KNIGHT THERAPS
Pharma Pharmaceuticals
KNIGHT THERAPS is a pharmaceutical company with 1 FDA-approved products.
2014
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules
KNIGHT THERAPS's Key Drugs
KNIGHT THERAPS's core commercial portfolio centers on IMPAVIDO — its most strategically important drugs approved in the last 15 years.
KNIGHT THERAPS's Recent FDA Approvals
New NDA/BLA approvals for KNIGHT THERAPS over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
KNIGHT THERAPS's Therapeutic Areas
Disease areas where KNIGHT THERAPS has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
KNIGHT THERAPS Pipeline Snapshot
Active clinical trials for KNIGHT THERAPS across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • IMPAVIDO leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2014-03-19
- Latest
- 2025-03-14
- Applications
- 1